Kura Oncology, Inc.
(NASDAQ : KURA)

( )
KURA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
-0.24%46.268.1%$690.49m
AMGNAmgen Inc.
-0.23%177.061.3%$495.97m
CELGCelgene Corporation
-0.72%90.871.3%$431.27m
GILDGilead Sciences, Inc.
-0.03%66.920.9%$401.89m
BIIBBiogen Inc.
-0.91%229.441.3%$372.09m
ILMNIllumina, Inc.
0.20%302.903.5%$354.87m
REGNRegeneron Pharmaceuticals, Inc.
0.35%299.422.6%$268.31m
ALXNAlexion Pharmaceuticals, Inc.
0.48%123.412.0%$197.95m
SRPTSarepta Therapeutics, Inc.
0.49%154.0014.7%$197.25m
VRTXVertex Pharmaceuticals Incorporated
0.56%177.141.9%$181.72m
AAgilent Technologies, Inc.
-0.52%69.591.6%$140.09m
EXASExact Sciences Corporation
1.21%116.3424.1%$137.96m
INCYIncyte Corporation
0.44%80.232.5%$110.35m
BLUEBluebird Bio, Inc.
4.33%139.4514.3%$97.87m
BMRNBioMarin Pharmaceutical Inc.
0.12%82.474.3%$84.42m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.